ME02477B - Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji - Google Patents
Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapijiInfo
- Publication number
- ME02477B ME02477B MEP-2016-163A MEP16316A ME02477B ME 02477 B ME02477 B ME 02477B ME P16316 A MEP16316 A ME P16316A ME 02477 B ME02477 B ME 02477B
- Authority
- ME
- Montenegro
- Prior art keywords
- therapeutic agent
- treatment
- use according
- compound
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Molecular Biology (AREA)
Claims (19)
1. Prvi terapijski agens predstavljen sledećom strukturalnom formulom: ili farmaceutski prihvatljiva so od toga, naznačeni time što su za korišćenje u lečenju Gošeove bolesti,u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Gošeove bolesti.
2. Korišćenje prvog terapijskog agensa predstavljenog sledećom strukturalnom formulom: ili farmaceutski prihvatljive soli od toga, naznačeno time što je za proizvodnju medikamenta za korišćenje u lečenju Gošeove bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Gošeove bolesti.
3. Jedinjenje za korišćenje prema Patentnom zahtevu 1 ili korišćenje prema Patentnom zahtevu 2, naznačeno time što se drugi terapijski agens odabere između glukocerebrozidaze, analoga glukocerebrozidaze, inhibitora glukozilceramid sintaze i molekulskih šaperona koji se vežu na glukocerebrozidazu i obnavljaju njenu ispravnu konformaciju.
4. Jedinjenje za korišćenje prema Patentnom zahtevu 1 ili korišćenje prema Patentnom zahtevu 2, naznačeno time što drugi terapijski agens je imigluceraza, izofagomin, miglustat, taligluceraza alfa ili velagluceraza alfa.
5. Prvi terapijski agens predstavljen sa sledećom strukturalnom formulom: ili farmaceutski prihvatljiva so od toga, naznačeni time što su za korišćenje u lečenju Fabrijeve bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Fabrijeve bolesti.
6. Korišćenje prvog terapijskog agensa predstavljenog sledećom strukturalnom formulom: ili farmaceutski prihvatljive soli od toga, naznačeno time što je za proizvodnju medikamenta za korišćenje u lečenju Fabrijeve bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Fabrijeve bolesti.
7. Jedinjenje za korišćenje prema Patentnom zahtevu 5 ili korišćenje prema Patentnom zahtevu 6, naznačeni time što se drugi terapijski agens odabere između α galaktozidaze A, analoga α galaktozidaze A i molekulskih šaperona koji se vežu na α galaktozidazu A i obnavljaju njenu ispravnu konformaciju.
8. Jedinjenje za korišćenje prema Patentnom zahtevu 5 ili korišćenje prema Patentnom zahtevu 6, naznačeni time što drugi terapijski agens je migalastat, agalzidaza beta ili agalzidaza alfa.
9. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 8, naznačeni time što se prvi terapijski agens primenjuje kao hemitartaratna so.
10. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 9, naznačeni time što je pomenuta so amorfna ili je barem 70% težinski pomenute soli kristalno.
11. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 9, naznačeni time što je barem 70% težinski pomenute soli u pojedinačnom kristalnom obliku.
12. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik karakterisan sa jednim, dva, tri, četiri ili pet glavnih vrhova difrakcije x-zraka na prahu pri 2θ uglovima od 5,1°, 6,6°, 10,7°, 11,0°, 15,9° i 21,7°.
13. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik karakterisan sa vrhovima difrakcije x-zraka na prahu pri 2θ uglovima od 5,1°, 6,6°, 10,7°, 11,0°, 13,3°, 15,1°, 15,9°, 16,5°, 17,6°, 18,6°, 18,7°, 19,0°, 20,2°, 21,7° i 23,5°.
14. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik is karakterisan sa uzorkom difrakcije x-zraka na prahu sa Slike 1.
15. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 14, naznačeni time što se lečenje sa prvim terapijskim agensom otpočne nakon lečenja tokom perioda od barem deset sedmica sa drugim terapijskim agensom.
16. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 14, naznačeni time što se lečenje sa prvim terapijskim agensom otpočne nakon lečenja sa drugim terapijskim agensom i u čemu se lečenje sa prvim terapijskim agensom otpočne nakon što je subjektov broj trombocita jednak ili veći od 100,000 mm3; koncentracija hemoglobina je jednaka ili veća od 11 g/dl (žensko) ili 12 g/dl (muško); i/ili je zapremina subjektove slezene manja od ili jednaka 10 količnika normale i zapremine jetre su manje od ili jednake 1,5 količnika normale.
17. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 15 ili 16, naznačeni time što se lečenje sa drugim terapijskim agensom završi nakon početka lečenjenja sa prvim terapijskim agensom.
18. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 17, naznačeni time što pomenuto lečenje obuhvata primenu prvog terapijskog agensa pri dvaput dnevno dozi od 25 miligrama do 200 miligrama.
19. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 18, naznačeni time što pomenuto lečenje obuhvata primenu prvog terapijskog agensa pri dvaput dnevno dozi od 50 miligrama. Crteži
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 | |
| EP14164650.5A EP2796457B1 (en) | 2009-11-27 | 2010-11-24 | Genz 112638 for treating Gaucher or Fabry disease in combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02477B true ME02477B (me) | 2017-02-20 |
Family
ID=43431870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-163A ME02477B (me) | 2009-11-27 | 2010-11-24 | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji |
Country Status (40)
| Country | Link |
|---|---|
| US (6) | US11458119B2 (me) |
| EP (5) | EP3896069A1 (me) |
| JP (6) | JP2013512252A (me) |
| KR (6) | KR20220162824A (me) |
| CN (5) | CN105777707B (me) |
| AR (3) | AR079152A1 (me) |
| AU (3) | AU2010324810B2 (me) |
| BR (1) | BR112012012947B8 (me) |
| CA (3) | CA3075788C (me) |
| CL (2) | CL2012001348A1 (me) |
| CR (1) | CR20120277A (me) |
| CY (3) | CY1115880T1 (me) |
| DK (3) | DK3133070T3 (me) |
| DO (2) | DOP2012000141A (me) |
| EA (3) | EA023923B1 (me) |
| EC (2) | ECSP12011926A (me) |
| ES (4) | ES2754398T3 (me) |
| GT (1) | GT201200161A (me) |
| HR (3) | HRP20140780T4 (me) |
| HU (2) | HUE029371T2 (me) |
| IL (4) | IL310635A (me) |
| LT (2) | LT2796457T (me) |
| MA (1) | MA33838B1 (me) |
| ME (1) | ME02477B (me) |
| MX (2) | MX358345B (me) |
| MY (2) | MY160542A (me) |
| NI (1) | NI201200096A (me) |
| NZ (3) | NZ625712A (me) |
| PE (2) | PE20121337A1 (me) |
| PH (2) | PH12012501048A1 (me) |
| PL (4) | PL2504332T5 (me) |
| PT (4) | PT2796457T (me) |
| RS (3) | RS59543B1 (me) |
| SG (2) | SG10201800136QA (me) |
| SI (3) | SI2796457T1 (me) |
| SM (1) | SMT201600273B (me) |
| TN (1) | TN2012000237A1 (me) |
| TW (3) | TWI606827B (me) |
| UA (1) | UA113491C2 (me) |
| WO (1) | WO2011066352A1 (me) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| MY160542A (en) | 2009-11-27 | 2017-03-15 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2012177778A1 (en) * | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
| ES2791760T3 (es) | 2011-09-07 | 2020-11-05 | Sinai School Medicine | Ceramidasa y diferenciación celular |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| CN109529028A (zh) | 2012-06-01 | 2019-03-29 | 西奈山伊坎医学院 | 在感染的治疗和预防中的神经酰胺水平 |
| DK2968479T3 (da) | 2013-03-14 | 2019-08-12 | Icahn School Med Mount Sinai | Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
| JP6537500B2 (ja) * | 2013-09-20 | 2019-07-03 | ビオマリン プハルマセウトイカル インコーポレイテッド | 疾患治療用のグルコシルセラミドシンターゼ阻害剤 |
| CA2954030A1 (en) * | 2014-07-03 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| EP3283483B1 (en) | 2015-04-14 | 2018-12-19 | Sandoz AG | Crystalline eliglustat hydrochloride |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| BR112018009879A2 (pt) | 2015-11-18 | 2018-11-13 | Genzyme Corp | biomarcador da doença renal policística e seus usos |
| KR102800480B1 (ko) | 2016-02-25 | 2025-04-25 | 아셰뉴론 에스아 | 피페라진 유도체의 산 부가 염 |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) * | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| ZA201803719B (en) | 2017-06-05 | 2019-04-24 | Cipla Ltd | Stable solid dispersions of eliglustat hemitartrate |
| EP3638241B1 (en) | 2017-06-16 | 2022-05-25 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| EP3664798B1 (en) * | 2017-08-08 | 2025-10-29 | Amneal Pharmaceuticals LLC | Pharmaceutical composition comprising eliglustat |
| US12472144B2 (en) * | 2017-08-08 | 2025-11-18 | Amneal Pharmaceuticals Llc | Pharmaceutical composition comprising eliglustat |
| MX2020006272A (es) | 2017-12-15 | 2020-09-14 | Genzyme Corp | Metodos para tratar la enfermedad de gaucher. |
| WO2019123476A1 (en) * | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| US11760741B2 (en) | 2018-05-02 | 2023-09-19 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| US20210113703A1 (en) * | 2018-05-27 | 2021-04-22 | Bioasis Technologies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| EP4366737A1 (en) * | 2021-07-05 | 2024-05-15 | Asceneuron SA | Medicaments comprising glycosidase inhibitors |
| CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
| WO2026006099A1 (en) | 2024-06-24 | 2026-01-02 | Genzyme Corporation | Eliglustat for the treatment of gaucher disease |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| NZ269847A (en) | 1993-08-13 | 1996-11-26 | Seikagaku Kogyo Co Ltd | 2-alkylamino-3-morpholino-1-propanol derivative in a composition for neuronal disease treatment |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| ES2149350T3 (es) | 1994-02-02 | 2000-11-01 | Liposome Co Inc | Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion. |
| DE69524592T2 (de) | 1994-06-10 | 2002-07-18 | Seikagaku Corp., Tokio/Tokyo | 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| CA2336549A1 (en) | 1998-07-27 | 2000-02-10 | Johns Hopkins University | Methods for treating conditions modulated by lactosylceramide |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| AU774960B2 (en) * | 1999-07-09 | 2004-07-15 | Regents Of The University Of Michigan, The | Amino ceramide-like compounds and therapeutic methods of use |
| US6977723B2 (en) | 2000-01-07 | 2005-12-20 | Transform Pharmaceuticals, Inc. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| HRP20020909A2 (en) | 2000-04-24 | 2004-08-31 | Teva Pharma | Zolpidem hemitartrate |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| BR0206400A (pt) | 2001-01-10 | 2005-01-18 | Univ Michigan | Compostos de amino ceramidas e seus usos em métodos terapêuticos |
| CA2435037A1 (en) * | 2001-01-18 | 2002-07-25 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
| ES2395463T3 (es) | 2001-07-16 | 2013-02-15 | Genzyme Corporation | Un inhibidor de N-acilesfingosina glucosiltransferasa |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| PT1423376E (pt) | 2001-08-08 | 2010-04-12 | Tobira Therapeutics Inc | Composto bicíclico, sua produção e utilização |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| JP2005535665A (ja) | 2002-07-09 | 2005-11-24 | ザ スクリプス リサーチ インスティテュート | 虚血および再灌流損傷を防止する方法 |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| DE602005027308D1 (de) * | 2004-01-27 | 2011-05-19 | Synthon Bv | Stabile salze von olanzapin |
| AU2005284727A1 (en) | 2004-09-17 | 2006-03-23 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
| CA2582022C (en) | 2004-09-30 | 2021-05-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
| MX2007004514A (es) | 2004-10-13 | 2007-05-09 | Pharmacia & Upjohn Co Llc | Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6 oxopirimidin-1(6h)-il]-n-(2-hidroxetil)-4-metilbenzamida. |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US20070088082A1 (en) * | 2005-09-28 | 2007-04-19 | Judith Aronhime | Polymorphic forms of ladostigil tartrate |
| WO2007040995A1 (en) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| HUE026057T2 (en) * | 2006-05-09 | 2016-05-30 | Genzyme Corp | Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| KR20090104862A (ko) * | 2007-01-12 | 2009-10-06 | 와이어쓰 | 정제내 정제 조성물 |
| MX2009010557A (es) * | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| EP2594563B1 (en) | 2007-05-31 | 2018-07-18 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| AU2009226083A1 (en) | 2008-03-19 | 2009-09-24 | Existence Genetics Llc | Genetic analysis |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| RS59908B1 (sr) | 2009-11-27 | 2020-03-31 | Adverio Pharma Gmbh | Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata |
| MY160542A (en) | 2009-11-27 | 2017-03-15 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| RU2014101626A (ru) | 2011-06-21 | 2015-07-27 | Новартис Аг | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Ceased
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active Ceased
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 MX MX2017011301A patent/MX381242B/es unknown
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 KR KR1020247041119A patent/KR20250005503A/ko active Pending
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 PH PH1/2012/501048A patent/PH12012501048A1/en unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active Active
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 PH PH1/2015/502514A patent/PH12015502514B1/en unknown
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active Ceased
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko not_active Ceased
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en not_active Ceased
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en not_active Revoked
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
-
2014
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en not_active Abandoned
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es not_active Application Discontinuation
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es not_active Application Discontinuation
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US12465586B2/en active Active
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| HRP20180436T1 (hr) | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| IL197393A (en) | History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013516493A5 (me) | ||
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| HRP20210474T1 (hr) | Režim primjene nitrokatehola | |
| RU2015135843A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| WO2008011426A3 (en) | Methods and medicaments for administration of ibuprofen | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| MX2009004579A (es) | Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido. | |
| MX2008011020A (es) | Compuestos de receptor sigma. | |
| JP2012504584A5 (me) |